McDonough takes the helm at T2:
This article was originally published in Clinica
President of Cytyc's business development subsidiary John McDonough has taken on the new role of CEO of T2 Biosystems, a Cambridge, Massachusetts-based start up developing portable diagnostic systems that combine nanotechnology with miniaturised MRI technology. Previously at Cytyc Development Corporation, Mr McDonough was responsible for corporate strategy, acquisitions and venture investments. In his new role, the CEO said he aims to help T2 achieve its objectives for 2008, which includes producing a prototype instrument and identifying and advancing multiple diagnostic tests to the preclinical stage of development.
You may also be interested in...
In an open letter to the European Commission, Parliament and Council presidents, more than 400 cosmetics companies and animal-rights groups accuse the European Chemicals Agency of effectively “shredding” the animal testing ban on cosmetics by requiring testing for certain chemicals under REACH.
Pink Sheet reporters and editors look at the UK MHRA’s surprising approval of the Pfizer/BioNTech coronavirus vaccine, as well as the US reaction, and discuss President-elect Joe Biden’s potential US FDA commissioner nominees.
Divesting the heart valve division will allow LivaNova to focus more resources on its neuromodulation, cardiopulmonary and circulatory support businesses.